Abstract OBJECTIVES: The objective of this study was to evaluate outcomes of induction therapy prior to an operation in patients with cT3 nonsmall-cell lung cancer (NSCLC).
INTRODUCTION
Lung cancer is the leading cause of cancer deaths among both men and women. In 2016, it was estimated that an additional 158 080 patients would die of the disease [1] . Non-small-cell lung cancer (NSCLC) comprises roughly 30% of newly diagnosed early stage (stage I/II) lung cancers each year [2] . Appropriately selected patients fit for surgery typically undergo an operation with or without neoadjuvant or adjuvant chemotherapy or radiation or both for curative intent [2] [3] [4] . However, current guidelines on the appropriate treatment and management of stage IIB lung disease remain controversial and, in some cases, unclear. This clinical equipoise represents a reflection of both the heterogeneity of the disease at this stage and a lack of prospective evidence to guide treatment.
In the most recent iteration of the American Joint Committee on Cancer (AJCC) staging system for NSCLC, there is an increasing emphasis on the size of the primary tumour, in that tumours >7 cm are now classified as T3 lesions, as opposed to the previous sixth classification, in which all tumours greater than 3 cm were binned into a T2 classification [5] . Because of the emphasis that previous studies placed on the relationship between tumour size and outcomes and the limited number of studies that evaluate treatment regimens for larger tumours, the proper management of these patients remains poorly defined [6] . In previous analyses of the surveillance, epidemiology and end results database, tumour size was shown to be an independent predictor for overall and disease-specific survival [7, 8] . The commonly held ideology that decreasing tumour size preoperatively through induction therapy assists in surgical resection and ultimately leads to enhanced overall survival is one that needs further evaluation. Previous single-or multi-institutional studies have shown a benefit for induction therapy but are limited by their lack of generalizability [9, 10] .
The purpose of this study was to evaluate the impact of induction therapy prior to an operation in comparison to surgical resection alone on the survival of patients with clinically large, node negative NSCLCs without the known presence of metastases. Particular attention was paid to the effect that induction therapy has on subsequent surgical resection.
MATERIALS AND METHODS

Data source
The university's institutional review board provided exempt status for this analysis of the National Cancer Database (NCDB) Participant User Files. The NCDB is a de-identified database jointly administered by the American Cancer Society and the American College of Surgeons Commission on Cancer. It contains over 1500 Commission on Cancer institutions and encompasses over 30 million patient records. This database serves as a nationwide resource to assess oncology outcomes and is robust enough to capture roughly 70% of all new cancer diagnoses in the USA annually [11] .
The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methods used nor for the conclusions drawn from these data by the investigators.
Patient selection
Adult patients with a single, primary cancer diagnosis of NSCLC who underwent surgical resection from 2006 to 2011 were queried from the NCDB participant user files. These patients were identified using International Classification of Diseases for Oncology, third Edition (ICD-O-3) topography and histological codes. Of these patients, those who had tumour sizes greater than 7 cm (cT3, seventh ed. AJCC), no clinically positive lymph nodes (cN0) and no signs of distant metastases (cM0) met the inclusion criteria. In patients staged using the sixth edition of the AJCC staging system, those staged as cT2 but with tumour size >7 cm were included in the analysis. Patients with T4 (invasion into surrounding structures) tumours, N1, N2 or N3 nodal disease status or with distant metastases were excluded from this retrospective cohort analysis. All patients underwent surgical resection involving either a lobectomy or pneumonectomy. Cohorts were generated based on whether subjects did or did not receive induction chemotherapy.
Variables
Patient baseline characteristics that were extracted from the NCDB included patient demographic, tumour, and treatment characteristics. The demographic information included patient age, gender, race, education and income quartile, treatment facility type, insurance status and Charlson-Deyo Comorbidity Index score. Tumour characteristics included pathological tumour and nodal status. Treatment and surgical end-points included adjuvant radiation and chemotherapy, extent of surgical resection, surgical approach, number of lymph nodes removed and surgical margin status. Extent of surgical resection included lobectomies (sleeve lobectomy, bilobectomy and standard lobectomy) and pneumonectomies (simple and extended). The surgical approach was categorized as either video-assisted thoracoscopic surgery, open procedure, or those converted to open surgery with intention-to-treat analysis. The primary end point of our study was overall survival among patients in these 2 treatment groups. Secondary end-points included 30-and 90-day mortality rates, 30-day readmission rates, surgical margin status, number of lymph nodes removed and hospital length of stay.
Statistical analysis
Baseline characteristics and outcomes were compared between groups using the Kruskal-Wallis analysis of variance test for continuous variables and Pearson's v 2 test for categorical variables. To adequately adjust for potential selection bias between an operation and induction, we developed propensity scores, which were defined as the conditional probability of undergoing induction chemotherapy prior to surgery. Patients were matched based on propensity scores using a 2:1 nearest neighbour algorithm (MatchIt: nonparametric preprocessing for parametric casual inference) using the following clinically significant variables: age, gender, race, Charlson-Deyo Comorbidity Index score, treatment facility type (community, comprehensive community, or academic/research), education quartile (bottom, second, third, top), income quartile (bottom, second, third, top), insurance status, tumour size, AJCC pathological T and N stages and use of adjuvant chemotherapy and radiotherapy. Outcomes between the propensity matched groups were then compared. Long-term survival between both the unadjusted and propensity matched groups was estimated using the Kaplan-Meier method. All analyses were conducted using R 3.0.1 (The R Foundation for Statistical Computing, Vienna, Austria) with a P-value < 0.05 indicating statistical significance.
RESULTS
A total of 3819 patients met the inclusion criteria, with 3236 (84.7%) undergoing an operation first and 583 (15.3%) receiving induction therapy prior to operative resection. Patients who underwent induction therapy before the operation tended to be younger (62 years vs 67 years) and less likely to have 2 or more comorbidities (10.3 vs 13.8%; all P-values < 0.001) compared to those who received the operation prior to adjuvant therapy. Additionally, patients receiving induction chemotherapy were more likely following resection to have lower pathological T and N stages, were less likely to receive adjuvant radiation (7.1% vs 18.4%) and chemotherapy (14.6% vs 46.1%) and were more likely to undergo an open operative approach (87.3% vs 78%; all P-values < 0.001) ( Table 1) . Patients receiving induction therapy were less likely to have positive operative margins postoperatively (6.7% vs 11.7%, P-value < 0.001) ( Table 2) . A total of 1026 events were noted in the unmatched analysis. 
Predictors of induction therapy
A multivariable logistic regression model was developed to determine predictors of induction chemotherapy in this cohort. Those patients who were younger, had a lower Charlson-Deyo score and had Medicare/Medicaid insurance were less likely to receive induction therapy prior to operative resection (Table 3) .
Propensity matched analysis
After propensity matching, patients who underwent induction chemotherapy were more likely to have a lower pathological T stage and less likely to have a lower pathological N stage (both P-values < 0.001). They are less likely to receive adjuvant radiation (6.9% vs 16.7%) and chemotherapy (13.6% vs 55.5%, both P-values < 0.001). These same patients were more likely to undergo an open operative approach (87.3% vs 77.8%, P = 0.005). Those receiving induction therapy were also less likely to have positive surgical margins (6.7% vs 10.0%, P = 0.03) after resection (Table 4) . A total of 386 events were recorded in the propensity matched cohort. Short-term outcomes, after propensity matching, were similar between the 2 groups. Within matched groups, we found that 30-day mortality (1.5% vs 2.6%, P = 0.15) and 30-day readmission rates (4.5% vs 4.5%, P = 0.99) were not significantly different; however, the 90-day mortality (3.4 vs 6.6%, P = 0.002) rate was significantly lower in those who underwent surgery without induction compared with those who received induction chemotherapy (Table 5) . Propensity matched overall survival between the 2 groups was also similar (5-year survival rate of 52.5% for operation-first cohort, 5-year survival rate 49.3% for the induction-therapy cohort, P = 0.116) (Fig. 1 ).
DISCUSSION
The current standard of therapy for early-stage NSCLC in appropriately selected patients is surgical resection, followed by adjuvant treatment, depending on the pathological features of the cancer.
With the recent reclassification of tumours >7 cm from T2 to T3 status and the staging from stage IB to stage IIB if node-negative, there is little evidence on the effects of neoadjuvant therapy in larger node negative tumours [5] . The use of neoadjuvant chemotherapy has only been shown in previous studies with small cohorts to be associated with improved oncologic outcomes in tumours with regionally advanced nodal disease [12, 13] . For example, in a phase II trial between 1996 and 1998, the Bimodality Lung Oncology Team demonstrated that induction chemotherapy with paclitaxel and carboplatin therapy in early-stage (as defined by cT2 N0, T1-2 N1, T3 N0-1) NSCLC was a safe and tolerable therapeutic regimen in comparison to surgical treatment alone [14] . Furthermore, in another small, randomized trial comparing preoperative chemotherapy to an operation alone by Depierre et al. [15] , a lower relative risk of distant disease recurrence (RR 0.54, 95% CI 0.33-0.88, P = 0.01) was notable in patients receiving preoperative induction therapy. Although these studies are helpful, they are limited by their sample size and lack of generalizability to appropriately assess the impact of induction chemotherapy on short-and long-term outcomes in patients with early-stage NSCLC. In this population-level analysis of patients with cT3N0M0 who either underwent a surgical procedure prior to adjuvant therapy or induction therapy prior to surgical resection, we observed no significant difference in overall survival following propensity matching. Of note, both surgical margin positivity (10.0% vs 6.9%, P = 0.04), and use of the video-assisted thoracoscopic surgery surgical approach (15.0% vs 10.9%, P = 0.005) were significantly different between those who underwent surgery prior to adjuvant therapy and those who received induction therapy prior to resection. In a study of the Society of Thoracic Surgeons Database from 2001 to 2010, Ceppa et al. [16] illustrated an increase in the use of the video-assisted thoracoscopic surgery surgical approach from 23 cases in 2001 to 3599 cases in 2009. This finding is of note because of the possibility that some surgeons may have requested medical oncologists to administer chemotherapy to allow for easier tumour manipulation for removal as well as the systemic benefits that the therapy provides. There were no significant differences in the short-term perioperative outcomes of 30-day mortality and 30-day readmission after adjusting.
A notable difference between those who received induction therapy and those who underwent resection prior to adjuvant therapy is the significant difference in the rate of positive margins and R0/1 resections. After propensity matching, those patients in the induction therapy cohort were less likely to have positive margins (6.9% vs 10.0%) and R1 resection (2.8% vs 5.3%) and more likely to have R0 resection (93.1% vs 90.0%, all P-values = 0.40). This study is the first to evaluate the impact of induction therapy on surgical margin status at a population level. These results can be used to develop a strategy regarding the use of induction therapy in cases in which there is concern that it may be technically challenging to perform R0 resection. The results of this study are in line with those of previous studies that have evaluated the impact of induction on outcomes at both an institutional and a national level [10, 17] . In a single-institution study of 71 patients with T3-T4/N0 NSCLC, Lococo et al. [18] found no significant difference in either long-term or 5-year disease-free survival between patients who received induction therapy versus those who had only a surgical procedure. This group also observed that a multimodal treatment regimen with induction therapy followed by an operation was safe, although there was no clear evidence of prognostic improvement in oncologic outcomes. In another analysis of 1301 patients undergoing either lobectomy or pneumonectomy for T3N0 NSCLC from 1999 to 2008 using the surveillance, epidemiology and end results database, Moreno et al. [19] demonstrated that neoadjuvant radiation before a surgical procedure was not associated with improvements in overall survival or lung cancer-specific survival. This study, however, did assume that neoadjuvant radiation was a proxy for chemoradiation therapy. Additionally, the surveillance, epidemiology and end results database does not delineate between clinical and pathological staging, thereby limiting the generalizability of the conclusions derived.
In a population level analysis of 1026 patients who underwent primary surgical therapy from 1999 to 2006, Liu et al. [20] demonstrated that neoadjuvant therapy appears to have no significant effect on the 5-year overall survival rate, similar to the results of our study. However, we felt this study missed a unique opportunity to evaluate surgical differences such as postoperative margin status as well as surgical approaches between the 2 treatment groups. Liu et al. excluded all patients who had positive surgical margins from their study and did not evaluate the impact of induction therapy on surgical conversion rates.
Our study demonstrated that, although patients undergoing induction therapy had a higher rate of open procedures, those who proceeded to an operation first had a 4 times higher rate of converting from a minimally invasive approach to an open procedure (7.2% vs 1.8%, P = 0.005) compared to those who received induction therapy. This finding may reflect a high rate at which unexpected findings are encountered intraoperatively in patients who have the operative procedure first.
To our knowledge, this study is the first population level analysis to examine short-term outcomes of patients with cT3N0M0 NSCLC who underwent induction therapy prior to an operation as well as what factors are predictive of induction therapy. We did not see a significant difference between the 30-day mortality rate and readmissions between the 2 groups, although the induction therapy group had increased rates of complete resection. No differences between these 2 treatment groups could be confirmed in analysing long-term overall survival. Of note, this study did not analyse the patients treated with induction therapy who did not undergo a surgical procedure for disease progression or drug toxicity. These findings have important implications today from an oncologic and chemotherapy exposure standpoint. Although additional studies are warranted, our study challenges current practices and in fact highlights the benefit of induction therapy in having lower rates of positive surgical margins and conversion from minimally invasive to open procedures.
Like all retrospective studies of large databases, our study has its limitations. First, the retrospective nature of this study makes it vulnerable to selection bias. Despite attempting to control for known patient demographic, clinical, tumour and treatment characteristics through our propensity matched analysis, there were inherent differences between comparison groups that would be thoroughly addressed with a powered randomized trial. Another notable limitation was the lack of disease-specific survival in the NCDB, which made overall survival the only possible option to determine long-term outcome. Due to the nature of the data set, the decision making behind proceeding with either treatment modality is unknown and could not be accounted for. The validation of this data set is limited, so there is an inherent possibility of coding errors within the data set.
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